Sun Pharma Advanced Research Company Q1FY22 loss at Rs. 61.37 Cr
The company posted net loss of Rs.56.69 crores for the period ended June 30, 2020.
The company posted net loss of Rs.56.69 crores for the period ended June 30, 2020.
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
Acquisition of A&C expands Aceto’s Western manufacturing footprint
Capital infusion to accelerate Earendil’s R&D platform
The company plans to submit the vaccine for regulatory review
The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials
The patent protects antiviral compounds developed by the company that inhibit Vacuolar ATPase (V-ATPase) activity in cells, a mechanism involved in viral infection pathways
Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders
The once-weekly treatment targets Type 2 Diabetes Mellitus (T2DM) with demonstrated efficacy and safety
Subscribe To Our Newsletter & Stay Updated